No abstract

Age, predominance of trigeminal PHN in V1 and continuous burning pain was common and similar to literature. Sensation was hampered with evident deficits of all sensory modalities in the affected trigeminal areas, especially V1.

No abstract

Although newer mutations on this and related disorders are continuously described, their clinical characterization has been restricted to the peripheral aspects of these conditions. A broader characterization of this rare disorder may contribute to better understand the mechanisms of the nociceptive and cognitive aspects of pain.

* Patients with HSRN may present with significant, silent dental disease. * A standard protocol is helpful when evaluating such patients. * If the opportunity arises, evaluation of pulp tissue may reveal an altered proportion of myelinated and unmyelinated nerve fibres. This may avoid the more estabilished sural nerve biopsy.

Topical treatments have gained popularity for general use as an adjunct to systemic drugs in neuropathic pain, but their use produces variable clinical results and local adverse events. Objective: To evaluate the safety and analgesic effect of a formulation of liposomal capsaicin (LC) (0.025%) in patients with post herpetic neuralgia (PHN). Method: Patients who remained symptomatic after first-and second-line treatment were randomized to receive LC for six weeks in a placebo-controlled, crossover design study. Clinical assessment was performed at baseline, in the second, fourth and sixth week of treatment. Results: Thirteen patients completed both treatment periods. Visual Analog Scale (VAS) was significantly decreased after the end of the study (p = 0.008), however the effect of treatment was not significant (p = 0.076). There was no difference on global impression of change and other pain characteristics. LC was safe and well tolerated. However, at the concentration used, its analgesic effects were marginal and not significant.Keywords: capsaicin, pain, neuralgia, analgesia, rash, adverse events. RESUMOOs tratamentos tópicos ganharam popularidade para uso geral como um adjuvante de medicamentos sistêmicos na dor neuropática, mas seu uso produz resultados clínicos variáveis e eventos adversos locais. Objetivo: Avaliar o efeito de segurança e analgesia de uma formulação de capsaicina lipossomal (LC) (0,025%) em pacientes com neuralgia pós-herpética. Método: Os pacientes que permaneceram sintomáticos após tratamento de primeira e de segunda linha foram randomizados para receber LC durante seis semanas em um estudo cruzado controlado por placebo. A avaliação clínica foi realizada no início do estudo, na segunda, quarta e sexta semana de tratamento. Resultados: Treze pacientes completaram dois períodos de tratamento. Escala Visual Analógica diminuiu significativamente após o final do estudo (p = 0,008), no entanto, o efeito do tratamento não era significativo (p = 0,076). Não houve diferença na impressão global de mudança e de outras características da dor. LC foi segura e bem tolerada. No entanto, para a concentração utilizada, os seus efeitos analgésicos foram marginais e não significativos.Palavras-chave: capsaicina, dor, neuralgia, analgesia, efeitos adversos.Neuropathic pain is present in 7% of the general population 1,2 , and despite the multiple treatment approaches, its current management only provides modest pain relief 3,4 . There has been renewed interest in the development of topical treatments that can decrease pain with lower side effects 4 . However, the use of topical treatments has provided variable analgesic results 5,6 and is associated with side effects mainly related to skin reactions and pain in the application site 7,8 . One approach to increase the therapeutic index (i.e., the measurement of efficacy over toxicity) is to employ delivery systems that can release the medication to its target with fewer side effects related to local inflammation 9 . Topical capsaicin has been used in th...

OBJECTIVE:This research was designed as a pilot proof-of-concept study to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line post-herpetic neuralgia treatments and had indications for adding an opioid agent to their current drug regimens.METHODS:This cross-over study was double blind and placebo controlled. Ten opioid naïve post-herpetic neuralgia patients received either methadone (5 mg bid) or placebo for three weeks, followed by a 15-day washout period and a second three-week treatment with either methadone or placebo, accordingly. Clinical evaluations were performed four times (before and after each three-week treatment period). The evaluations included the visual analogue scale, verbal category scale, daily activities scale, McGill pain questionnaire, adverse events profile, and evoked pain assessment. All patients provided written informed consent before being included in the study. ClinicalTrials.gov: NCT01752699RESULTS:Methadone, when compared to placebo, did not significantly affect the intensity of spontaneous pain, as measured by the visual analogue scale. The intensity of spontaneous pain was significantly decreased after the methadone treatment compared to placebo on the category verbal scale (50% improved after the methadone treatment, none after the placebo, p = 0.031). Evoked pain was reduced under methadone compared to placebo (50% improved after the methadone treatment, none after the placebo, p = 0.031). Allodynia reduction correlated with sleep improvement (r = 0.67, p = 0.030) during the methadone treatment. The side effects profile was similar between both treatments. CONCLUSIONS:Methadone seems to be safe and efficacious in post-herpetic neuralgia. It should be tried as an adjunctive treatment for post-herpetic neuralgia in larger prospective studies.

Os objetivos deste estudo foram descrever um programa extracurricular de educação em dor, organizado na forma de Liga, e identificar a opinião dos alunos sobre esse modelo de ensino. O Estatuto e o Regimento Interno da Liga de Dor foram as fontes e dados para a descrição da sua organização e funcionamento. Todos os alunos que frequentaram a Liga de Dor nos anos de 1995 e 1996 foram solicitados a responder um questionário sobre suas experiências na Liga. A Liga de Dor foi organizada sob o patrocínio do Centro Acadêmico Osvaldo Cruz, da Faculdade de Medicina da USP, e Centro Acadêmico XXXI de Outubro, da Escola de Enfermagem da USP, em 1995. É composta por alunos dessas duas faculdades e profissionais enfermeiros e médicos, de várias especialidades. Todas as atividades são voluntárias, desenvolvidas em período extracurricular e os estudantes dirigem a Liga. Os objetivos da Liga são: melhorar a qualidade do ensino sobre dor nas escolas médica e de enfermagem, desenvolver pesquisas relativas à epidemiologia, clínica e controle da dor e promover modelo de assistência multidisciplinar e multiprofissional. A maioria dos alunos expressou ter alcançado seus objetivos, total ou parcialmente; ter aumentado seu conhecimento sobre as síndromes álgicas e sobre o manejo do doente com dor; sentir-se gratificado com sua atividade; que o tema dor deveria ser incluído no currículo de modo mais específico e que recomendaria a outros colegas a participação na Liga de Dor. As opiniões dos estudantes mostraram que a Liga de Dor pode ser um modelo útil para a introdução do ensino da dor nos cursos de graduação e enfermagem e de medicina.